Stephens Lowers Certara (NASDAQ:CERT) Price Target to $9.00

Posted by George Bondi on May 14th, 2026

Certara (NASDAQ:CERT – Get Free Report) had its price target lowered by investment analysts at Stephens from $10.00 to $9.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Stephens’ target price would indicate a potential upside of 87.89% from the stock’s previous close.

Several other analysts have also issued reports on CERT. TD Cowen reiterated a “buy” rating on shares of Certara in a research report on Thursday, February 26th. Craig Hallum downgraded shares of Certara from a “buy” rating to a “hold” rating and set a $10.00 price objective for the company. in a research report on Friday, February 27th. Wall Street Zen cut Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. KeyCorp reduced their target price on Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday, April 13th. Finally, Barclays decreased their price target on Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.85.

Check Out Our Latest Report on Certara

Certara Stock Down 5.9%

CERT stock opened at $4.79 on Tuesday. Certara has a 52 week low of $4.78 and a 52 week high of $13.88. The business has a 50-day simple moving average of $6.13 and a 200 day simple moving average of $7.91. The company has a quick ratio of 2.05, a current ratio of 1.88 and a debt-to-equity ratio of 0.28. The company has a market cap of $745.18 million, a PE ratio of -47.90 and a beta of 1.53.

Certara (NASDAQ:CERT – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The firm had revenue of $106.92 million for the quarter, compared to analyst estimates of $106.13 million. During the same quarter in the previous year, the company earned $0.14 earnings per share. The company’s quarterly revenue was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Sell-side analysts anticipate that Certara will post 0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CERT. Wasatch Advisors LP lifted its stake in shares of Certara by 28.6% in the 3rd quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock valued at $212,608,000 after acquiring an additional 3,865,455 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Certara by 2.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock worth $48,806,000 after purchasing an additional 175,024 shares in the last quarter. Deerfield Management Company L.P. raised its position in Certara by 71.7% in the third quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock valued at $82,357,000 after purchasing an additional 2,813,438 shares during the last quarter. Geneva Capital Management LLC boosted its stake in shares of Certara by 0.7% during the third quarter. Geneva Capital Management LLC now owns 6,160,754 shares of the company’s stock valued at $75,284,000 after purchasing an additional 45,859 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in shares of Certara by 27.1% during the second quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after purchasing an additional 1,165,064 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Key Certara News

Here are the key news stories impacting Certara this week:

Positive Sentiment: Certara said its AI-related investments should support long-term growth, which could help investor confidence over time. Certara says AI investments will drive long-term growth – but traders are focused on one warning
Neutral Sentiment: Certara announced expected 2026 revenue of $395 million to $405 million following its medical writing divestiture, giving investors a clearer forward outlook, though the range appears modest. Certara expects $395M-$405M 2026 revenue following medical writing divestiture
Negative Sentiment: Several firms lowered price targets on Certara, including Morgan Stanley, Stephens, Craig Hallum, Barclays, and Robert W. Baird, signaling reduced near-term enthusiasm for the stock. Certara (NASDAQ:CERT) Price Target Lowered to $10.00 at Morgan Stanley
Negative Sentiment: Analysts cut Certara’s valuation after the earnings update, with targets reduced to $9.00 from Stephens and $8.00 from Craig Hallum, reinforcing pressure on the shares. Certara (NASDAQ:CERT) Given New $9.00 Price Target at Stephens
Negative Sentiment: Certara was said to have hit a new 52-week low after missing earnings expectations, highlighting investor concern about profitability. Certara (NASDAQ:CERT) Hits New 52-Week Low After Earnings Miss

Certara Company Profile

(Get Free Report)

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.